BioHealth News

Gaithersburg’s Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

Gaithersburg’s Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce…

Read More
Rockville’s REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

Rockville’s REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

ROCKVILLE, Md., May 23, 2023 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT)…

Read More
Maryland Stem Cell Research Commission Announces Over $14 Million in Awards to Accelerate Cures

Maryland Stem Cell Research Commission Announces Over $14 Million in Awards to Accelerate Cures

Commission also issues Request for Applications for Four Funding Programs for July 13, 2023, Deadline COLUMBIA, Md. (May 9, 2023) —The Maryland Stem Cell Research…

Read More
TEDCO Announces Investment into CarrTech Corp.

TEDCO Announces Investment into CarrTech Corp.

Maryland medical device company supports patients and medical professionals through safer needle filtration device COLUMBIA, Md. (May 22, 2023) – TEDCO, Maryland’s economic engine…

Read More
JLL Life Sciences Observations Suburban Maryland Q1 2023

JLL Life Sciences Observations Suburban Maryland Q1 2023

Summary and analysis of Maryland's suburban current economic and office real estate market conditions. Click here to read the entire report.

Read More
Harsha Rajasimha, PhD, founder and CEO of Jeeva Informatics discusses current challenges leading to clinical trial delays, such as the “valley of death.”

Harsha Rajasimha, PhD, founder and CEO of Jeeva Informatics discusses current challenges leading to clinical trial delays, such as the “valley of death.”

Pharmacy Times® interviewed Harsha Rajasimha, PhD, founder and CEO of Jeeva Informatics, on the potential to accelerate patient recruitment and solve clinical trial delays. Currently,…

Read More
TEDCO Announces SSBCI Investment into N5 Sensors

TEDCO Announces SSBCI Investment into N5 Sensors

Maryland-based business protecting individuals and businesses from environmental hazards through the use of its innovative sensor technology COLUMBIA, Md. (May 22, 2023) – TEDCO, Maryland’s…

Read More
From Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions, Joins BioTalk

From Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions, Joins BioTalk

Can you envision a world where precision medicine transforms healthcare as we know it? Tune in to this exciting episode of BioTalk with Rich…

Read More
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee

Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee

RICHMOND, VA – May 18, 2023 – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it…

Read More
PQE Group US Earns 2023 Great Place To Work Certification™

PQE Group US Earns 2023 Great Place To Work Certification™

PQE Group receives certification in the U.S. as a work environment where “you trust the people you work for, take pride in what you…

Read More
Baltimore’s Flavocure Biotech Announces FDA Clearance of IND Application for Caflanone (FBL-03G), for Clinical Trials in Pancreatic Cancer Patients.

Baltimore’s Flavocure Biotech Announces FDA Clearance of IND Application for Caflanone (FBL-03G), for Clinical Trials in Pancreatic Cancer Patients.

Baltimore, Maryland--(Newsfile Corp. - May 17, 2023) - Flavocure Biotech, Inc. ("Flavocure"), today announced that it has received clearance of its Investigational New Drug…

Read More
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium’s First Rare Disease Clinical Portfolio

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium’s First Rare Disease Clinical Portfolio

ROCKVILLE, Md., May 16, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known…

Read More
Role of global public sector research in discovering new drugs and vaccines

Role of global public sector research in discovering new drugs and vaccines

Analysis of international public-sector contributions to Food and Drug Administration (FDA)-approved drugs and vaccines allows for a more thorough examination of the global biomedical…

Read More
President Biden Announces Intent to Nominate Dr. Monica Bertagnolli as Director of the National Institutes of Health

President Biden Announces Intent to Nominate Dr. Monica Bertagnolli as Director of the National Institutes of Health

Today (May 15, 2023), President Biden announced his intent to nominate Dr. Monica Bertagnolli as Director of the National Institutes of Health (NIH), the…

Read More
BHI/NIH EIR Anna Zornosa Moderates Panel of Experts: Unlocking Reimbursement for Innovators in Maternal Health Solutions

BHI/NIH EIR Anna Zornosa Moderates Panel of Experts: Unlocking Reimbursement for Innovators in Maternal Health Solutions

Reimbursement is key to the success of innovators who have products, therapies, and new modes of service for expectant and new mothers. Not only…

Read More